CN Patent

CN106243113A — 作为btk抑制剂的选择的咪唑并吡嗪类

Assigned to Merck Sharp and Dohme BV · Expires 2016-12-21 · 9y expired

What this patent protects

本发明涉及作为BTK抑制剂的选择的咪唑并吡嗪类，具体涉及式I的6‑5元稠合吡啶环化合物 或其药学上可接受的盐或涉及含有这类化合物的药物组合物以及涉及它们在治疗中的用途。本发明特别涉及式I的6‑5元稠合吡啶环化合物在治疗布鲁顿酪氨酸激酶(Btk)介导的病症中的用途。

USPTO Abstract

本发明涉及作为BTK抑制剂的选择的咪唑并吡嗪类，具体涉及式I的6‑5元稠合吡啶环化合物 或其药学上可接受的盐或涉及含有这类化合物的药物组合物以及涉及它们在治疗中的用途。本发明特别涉及式I的6‑5元稠合吡啶环化合物在治疗布鲁顿酪氨酸激酶(Btk)介导的病症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN106243113A
Jurisdiction
CN
Classification
—
Expires
2016-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.